Clinical trial
A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
NCT03060980 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Lead sponsor
- Intarcia Therapeutics
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- March 3, 2017
- Completion date
- January 26, 2018
- Enrollment
- 245 (actual)
- Sites
- 101
Conditions
As the registry lists them; a condition with its own page is linked.